等待開盤 07-23 09:30:00 美东时间
+0.610
+0.85%
今日重点评级关注:DA Davidson:维持Almonty Industries"买入"评级,目标价从25美元升至33美元;Stifel:维持Nurix Therapeutics"买入"评级,目标价从34美元升至40美元
07-13 10:13
Goldman Sachs analyst Susan Maklari maintains Meritage Homes (NYSE:MTH) with a Buy and raises the price target from $82 to $93.
07-10 23:02
Zelman & Assoc analyst Ivy Zelman downgrades Meritage Homes (NYSE:MTH) from Outperform to Neutral.
07-07 23:27
Meritage ( ($MTH) ) has provided an update. On June 24, 2026, Meritage Homes Co...
06-30 05:03
Meritage Homes Corporation, the fifth-largest U.S. homebuilder, will release its Q2 2026 results on July 29, 2026, followed by a conference call on July 30 at 8:00 a.m. PT (11:00 a.m. ET). Investors can join via webcast or dial-in using the conference code MTHQ226. Meritage, known for energy-efficient and affordable homes, operates across 12 states and has delivered over 210,000 homes, earning multiple EPA awards for sustainability.
06-11 21:00
Berkshire Hathaway's (BRK.A) (BRK.B) agreement to acquire Taylor Morrison Home (TMHC) in an $8.5B all-cash deal has renewed investor focus on the U.S. homebuilding sector, even as elevated mortgage ra...
06-01 14:53
Meritage Homes, the fifth-largest U.S. homebuilder, continues its partnership with Operation Homefront’s Permanent Homes for Veterans Program for the 13th year, providing a mortgage-free home to a military family in Gulfport, Mississippi. Since 2013, Meritage has donated 22 homes to veterans. This year’s home, located in the Hidden Trails community, features four bedrooms, three bathrooms, and a two-car garage, with easy access to shopping, dinin...
05-26 13:00
Meritage Homes (MTH) declares $0.48/share quarterly dividend, in line with previous. Forward yield 3.01% Payable June 30; for shareholders of record June 16; ex-div June 16. See MTH Dividend Scorecard...
05-22 19:32
Homebuilding stocks were surging after the House passed a new version of the housing bill. The amended bill includes restrictions on institutional investors buying single-family homes, but removes a r...
05-21 02:14
今日重点评级关注:Canaccord Genuity:维持Intellia Therapeutics"买入"评级,目标价从48美元升至58美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从7美元升至8美元
04-29 10:28